Gerardo García-Díaz Barriga

Gerardo García-Díaz Barriga

Auto-generated profile, based on publicly available information

Gerardo García-Díaz Barriga

Evotec SE, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2017 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
TCThe HD iPSC Consortium
The HD iPSC Consortium
RLRyan G Lim
Ryan G Lim
LSLisa L Salazar
Lisa L Salazar
DWDaniel K Wilton
Daniel K Wilton
AKAlvin R King
Alvin R King
CSClive N Svendsen
Clive N Svendsen
The Huntington's disease (HD) induced pluripotent stem cell (iPSC) consortium describe the combined use of differentiated patient-derived iPSCs and systems biology to discover underlying mechanisms in HD. They identify neurodevelopmental deficits in HD cells that can be corrected in cells and in vivo with a small molecule. Neural cultures derived from Huntington's disease (HD) patient-derived induced pluripotent stem cells were used for 'omics' analyses to identify mechanisms underlying neurodegeneration. RNA-seq analysis identified genes in glutamate and GABA signaling, axonal guidance and calcium influx whose expression was decreased in HD cultures. One-third of gene changes were in pathways regulating neuronal development and maturation. When mapped to stages of mouse striatal development, the profiles aligned with earlier embryonic stages of neuronal differentiation. We observed a strong correlation between HD-related histone marks, gene expression and unique peak profiles associated with dysregulated genes, suggesting a coordinated epigenetic program. Treatment with isoxazole-9, which targets key dysregulated pathways, led to amelioration of expanded polyglutamine repeat-associated phenotypes in neural cells and of cognitive impairment and synaptic pathology in HD model R6/2 mice. These data suggest that mutant huntingtin impairs neurodevelopmental pathways that could disrupt synaptic homeostasis and increase vulnerability to the pathologic consequence of expanded polyglutamine repeats over time.

10 June 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
AMAndrés Miguez
Andrés Miguez
GBGerardo García-Díaz Barriga
Gerardo García-Díaz Barriga
VBVerónica Brito
Verónica Brito
MSMarco Straccia
Marco Straccia
AGAlbert Giralt
Albert Giralt
JAJordi Alberch
Jordi Alberch
Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by motor and cognitive impairments, involving striatum, cortex and hippocampus. Synaptic and memory dysfunction in HD mouse models have been related to low levels of brain-derived neurotrophic factor (BDNF) and imbalance between TrkB and p75NTR receptors. In addition, astrocyte over-activation has also been suggested to contribute to HD cognitive deficits. Fingolimod (FTY720), a modulator of sphingosine-1 phosphate (S1P) receptors, has been shown to increase BDNF levels and to reduce astrogliosis, proving its potential to regulate trophic support and inflammatory response. In this view, we have investigated whether FTY720 improves synaptic plasticity and memory in the R6/1 mouse model of HD, through regulation of BDNF signaling and astroglial reactivity. Chronic administration of FTY720 from pre-symptomatic stages ameliorated long-term memory deficits and dendritic spine loss in CA1 hippocampal neurons from R6/1 mice. Furthermore, FTY720 delivery prevented astrogliosis and over-activation of nuclear factor kappa beta (NF-κB) signaling in the R6/1 hippocampus, reducing tumor necrosis factor alpha (TNFα) and induced nitric oxide synthase (iNOS) levels. TNFα decrease correlated with the normalization of p75NTR expression in the hippocampus of FTY720-treated R6/1 mice, thus preventing p75NTR/TrkB imbalance. In addition, FTY720 increased cAMP levels and promoted phosphorylation of CREB and RhoA in the hippocampus of R6/1 mice, further supporting its role in the enhancement of synaptic plasticity. Our findings provide new insights into the mechanism of action of FTY720 and reveal a novel therapeutic strategy to treat memory deficits in HD.

1 March 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
JFJuan C. Fraire
Juan C. Fraire
GHGaëlle Houthaeve
Gaëlle Houthaeve
JLJing Liu
Jing Liu
LRLaurens Raes
Laurens Raes
LVLotte Vermeulen
Lotte Vermeulen
Kevin BraeckmansKevin Braeckmans
Kevin Braeckmans

31 July 2019 in Brain
Verified
Journal Article
Closed access
JCJordi Creus-Muncunill
Jordi Creus-Muncunill
RBRaquel Badillos-Rodríguez
Raquel Badillos-Rodríguez
MGMarta Garcia-Forn
Marta Garcia-Forn
MMMercè Masana
Mercè Masana
GBGerardo Garcia-Díaz Barriga
Gerardo Garcia-Díaz Barriga
EPEsther Pérez-Navarro
Esther Pérez-Navarro
See Brouillet and Merienne (doi:10.1093/brain/awz274) for a scientific commentary on this article.Creus-Muncunill et al. report that protein translation is altered in the striatum of Huntington’s disease mouse models, with upregulated expression of proteins from ribosomal and oxidative phosphorylation pathways. Pharmacological normalization of protein translation in R6/1 mice ameliorates motor disturbances and normalizes ribosomal content in the striatum.

24 May 2017 in Human Molecular Genetics
Verified
Journal Article
Closed access
GBGerardo García-Díaz Barriga
Gerardo García-Díaz Barriga
AGAlbert Giralt
Albert Giralt
MAMarta Anglada-Huguet
Marta Anglada-Huguet
NGNúria Gaja-Capdevila
Núria Gaja-Capdevila
JOJavier G. Orlandi
Javier G. Orlandi
JAJordi Alberch
Jordi Alberch
Huntington's disease (HD) is a fatal neurodegenerative disease with motor, cognitive and psychiatric impairment. Dysfunctions in HD models have been related to reduced levels of striatal brain-derived neurotrophic factor (BDNF) and imbalance between its receptors TrkB and p75(NTR). Thus, molecules with activity on the BDNF/TrkB/p75 system can have therapeutic potential. 7,8-Dihydroxyflavone (7,8-DHF) was described as a TrkB agonist in several models of neuro-degenerative diseases, however, its TrkB activation profile needs further investigation due to its pleiotropic properties and divergence from BDNF effect. To investigate this, we used in vitro and in vivo models of HD to dissect TrkB activation upon 7,8-DHF treatment. 7,8-DHF treatment in primary cultures showed phosphorylation of TrkBY816 but not TrkBY515 with activation of the PLCγ1 pathway leading to morphological and functional improvements. Chronic administration of 7,8-DHF delayed motor deficits in R6/1 mice and reversed deficits on the Novel Object Recognition Test (NORT) at 17 weeks. Morphological and biochemical analyses revealed improved striatal levels of enkephalin, and prevention of striatal volume loss. We found a TrkBY816 but not TrkBY515 phosphorylation recovery in striatum concordant with in vitro results. Additionally, 7,8-DHF normalized striatal levels of induced and neuronal nitric oxide synthase (iNOS and nNOS, respectively) and ameliorated the imbalance of p75/TrkB. Our results provide new insights into the mechanism of action of 7,8-DHF suggesting that its effect through the TrkB receptor in striatum is via selective phosphorylation of its Y816 residue and activation of PLCγ1 pathway, but pleiotropic effects of the drug also contribute to its therapeutic potential.

31 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MPMarta Pulido-Salgado
Marta Pulido-Salgado
JTJose Manuel Manuel Vidal Taboada
Jose Manuel Manuel Vidal Taboada
GBGerardo Garcia-Diaz Barriga
Gerardo Garcia-Diaz Barriga
CSCarme Solà
Carme Solà
JSJosep Saura
Josep Saura
Microglia, the main resident immune cells in the CNS, are thought to participate in the pathogenesis of various neurological disorders. LPS and LPS + IFNγ are stimuli that are widely used to activate microglia. However, the transcriptomic profiles of microglia treated with LPS and LPS + IFNγ have not been properly compared. Here, we treated murine primary microglial cultures with LPS or LPS + IFNγ for 6 hours and then performed RNA-Sequencing. Gene expression patterns induced by the treatments were obtained by WGCNA and 11 different expression profiles were found, showing differential responses to LPS and LPS + IFNγ in many genes. Interestingly, a subset of genes involved in Parkinson’s, Alzheimer’s and Huntington’s disease were downregulated by both treatments. By DESeq analysis we found differentially upregulated and downregulated genes that confirmed LPS and LPS + IFNγ as inducers of microglial pro-inflammatory responses, but also highlighted their involvement in specific cell functions. In response to LPS, microglia tended to be more proliferative, pro-inflammatory and phagocytic; whereas LPS + IFNγ inhibited genes were involved in pain, cell division and, unexpectedly, production of some inflammatory mediators. In summary, this study provides a detailed description of the transcriptome of LPS- and LPS + IFNγ treated primary microglial cultures. It may be useful to determine whether these in vitro phenotypes resemble microglia in in vivo pathological conditions.